October 03, 2023
The Therapeutics Accelerator (the ‘Accelerator’) will identify, fund and advance innovative projects from academic partners in the U.K. and U.S. with the goal to deliver 40 new potentially life-changing therapies for rare diseases into clinical trials over the next ten years, targeting multiple approvals in key...
Continue Reading
October 11, 2021
Dystonias are a group of chronic movement–disabling disorders for which highly effective oral medications or disease-modifying therapies are lacking. The availability of an oral drug with disease-modifying potential would transform the current treatment landscape. 2015 Harrington Scholar-Innovator Nicole Calakos, MD, PhD... Continue Reading
October 11, 2021
Huntington’s Disease (HD) is a fatal neurological disorder caused by a trinucleotide CAG repeat expansion in the N-terminal exon 1 of the huntingtin (Htt) gene. HD manifests as uncontrolled involuntary movements accompanied by progressive motor and cognitive deficits, psychiatric disturbance, and dementia. There is no therapy... Continue Reading
August 19, 2021
Scientists on either side of the Atlantic have teamed up, through the new (OHC), to address unmet needs in rare disease research and deliver “major clinical impact” to patients.And now, the international collaboration between the University of Oxford, in England, and the Harrington Discovery Institute, in Cleveland, Ohio... Continue Reading
August 18, 2021
CLEVELAND—Metabolic syndrome is a cluster of conditions and includes obesity, and can be dangerous as it increases the risk for heart disease, stroke, diabetes and other diseases. In a recent study, published in , researchers at Harrington Discovery Institute at University Hospitals (UH) have discovered a therapeutic option... Continue Reading
May 30, 2021
Preclinical program targeting 15-PGDH has potential use in a broad range of therapeutic applications including inflammatory disease indications Continue Reading
March 29, 2021
NEW YORK, NY, March 29, 2021—The Rockefeller University has received supplemental grant support from the Harrington Discovery Institute to help fund the testing of a monoclonal antibody drug for the prevention and early treatment of COVID-19. The drug is the result of a collaborative research effort launched in the first... Continue Reading
March 24, 2021
Cleveland, Ohio – The eighth annual Harrington Prize for Innovation in Medicine has been jointly awarded to Warren J. Leonard, MD, NHLBI, NIH Distinguished Investigator, and John J. O’Shea, MD, Scientific Director, NIAMS, NIH, for their respective contributions to the field of immunology, from fundamental discovery to... Continue Reading
March 15, 2021
CLEVELAND, Ohio USA – The 2022 Harrington Scholar-Innovator Award is now open and accepting Letters of Intent. The award offers inventive physician-scientists resources and expertise to advance their discoveries into medicines. Intellectual property rights are retained by the award recipient or his or her institution. Up to... Continue Reading
March 02, 2021
Cleveland, Ohio – Harrington Discovery Institute at University Hospitals and the Alzheimer's Drug Discovery Foundation (ADDF) announce a joint request for proposals for the . The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, or slow Alzheimer's... Continue Reading
February 18, 2021
CLEVELAND, OH—The transatlantic, not-for-profit medical accelerator, Harrington Discovery Institute at University Hospitals, has collaborated with leading venture investor, Advent Life Sciences (‘Advent’) in the launch of the Advent-Harrington Impact Fund.Advent’s new impact fund, structured alongside Advent Life... Continue Reading